martedì, 11 marzo 2025
Medinews
13 Dicembre 2019

FDA Approves Generic Everolimus Tablets

December 10, 2019 – The FDA has approved 2 abbreviated new drug applications (ANDAs) for everolimus tablets for the treatment of patients with advanced hormone receptor–positive, HER2-negative breast cancer in postmenopausal women; advanced renal cell carcinoma; progressive neuroendocrine tumors (NETs) of pancreatic origin; and progressive, well-differentiated, non-functional NETs of gastrointestinal or lung origin that are unresectable; and … (leggi tutto)

TORNA INDIETRO